Medical device, Partnering

Eisai and Biogen Idec ink a pharma deal for Alzheimer’s disease

Posted on 06 March 2014

Tags: , , ,

Eisai and Biogen Idec have entered into a pharma deal to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401.

The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec’s candidates for AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

The collaboration initially will be centered on the co-development and co-commercialization of Eisai’s two candidates.

E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody.

These candidates have the potential to reduce Aβ plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression.

Eisai will serve as the operational and regulatory lead in the co-development of E2609 and BAN2401 and will pursue marketing authorizations for both compounds worldwide.

In major markets, such as the United States and the European Union, Eisai and Biogen Idec will also co-promote the products following marketing approval.

Both companies will share overall costs, including research and development expenses, with Eisai booking all sales for E2609 and BAN2401 and with profits to be split between the companies.

Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments.

The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.

Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments.

The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.

 

For further deal information visit Current Agreements (subscription required)

Related

Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news – latest deal news for top 50 pharma / big pharma companies

Report: Practical Guide to Finding Partners

Report: Partnering Deals and Alliances with Big Pharma

Report: Partnering Deals and Alliances with Eisai

Report: Partnering Deals and Alliances with Biogen Idec

Related reports: Bigpharma Partnering Yearbook 2013

Related reports: Bigbiotech Partnering Yearbook 2013

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply